Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience

Venetoclax (VEN) has been shown to play a synergistic effect in combination with hypomethylating agents (HMAs) in the frontline treatment of acute myeloid leukemia (AML). However, the potential role of this therapy in the relapsed/refractory (R/R) AML setting, still needs to be further unveiled. The...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Francesco Angotzi, Federica Lessi, Matteo Leoncin, Carla Filì, Mauro Endri, Albana Lico, Andrea Visentin, Stefano Pravato, Anna Candoni, Livio Trentin, Carmela Gurrieri
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-04-01
Serija:	Frontiers in Oncology
Teme:	acute myeloid leukemia venetoclax hypomethylating agents azacitidine decitabine relapsed/refractory acute myeloid leukemia
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1370405/full
Oznake:	Označite Brez oznak, prvi označite!